Cargando…
Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS)
BACKGROUND: Many of the painful, disabling features of early diffuse cutaneous systemic sclerosis have an inflammatory component and are potentially treatable with corticosteroid therapy. These features include painful and itchy skin, fatigue and musculoskeletal involvement. Yet many clinicians are...
Autores principales: | Herrick, Ariane L, Griffiths-Jones, Deborah J, Ryder, W David, Mason, Justin C, Denton, Christopher P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216311/ https://www.ncbi.nlm.nih.gov/pubmed/34222671 http://dx.doi.org/10.1177/2397198320957552 |
Ejemplares similares
-
A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS)
por: Griffiths-Jones, Deborah J, et al.
Publicado: (2023) -
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need
por: Herrick, Ariane L., et al.
Publicado: (2022) -
Information preferences about treatment options in diffuse cutaneous systemic sclerosis: A Delphi consensus study
por: Spierings, Julia, et al.
Publicado: (2021) -
Patient perception of disease burden in diffuse cutaneous systemic
sclerosis
por: Khanna, Dinesh, et al.
Publicado: (2019) -
Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination
por: Cole, Alice, et al.
Publicado: (2022)